• CLINUVEL will renew its share buy-back program for 12 months
• Up to 1,500,000 ordinary shares, representing 3% of outstanding capital, can be repurchased
• Prudent cash management remains a priority, with opportune moments to support shareholders

CLINUVEL Pharmaceuticals Ltd has announced the renewal of its share buy-back program for a further 12 months, allowing for the repurchase of up to 1,500,000 ordinary shares, representing approximately 3.0% of its outstanding share capital. The Board is committed to ensuring all available tools are in place to achieve valuations that reflect CLINUVEL's business and progress. In an uncertain macroeconomic environment, prudent cash management remains a priority. However, there may be opportune moments to use capital to support the company's shareholders through an on-market share buy-back. The timing, amount, and pricing of any shares bought back will depend on market conditions and other factors. CLINUVEL does not intend to be in the market at all times during the buy-back period, and any repurchases will be made at the company's discretion. There is no guarantee that the company will buy back the full 3% of its issued capital under the buy-back program, and the company reserves the right to suspend or terminate the buy-back at any time.